TELO vs TARA vs ADTX vs NKTR vs ICLR

For growth investors, ICON Public Limited Company (ICLR) is the stronger pick with 2.

0% revenue growth year-over-year, versus -79. 2% for Aditxt, Inc. (ADTX). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Protara Therapeutics, Inc. (TARA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protara Therapeutics, Inc.

(TARA) delivered a total return of -45. 4%, compared to -100. 0% for Aditxt, Inc. (ADTX). Over 10 years, the gap is even starker: ICLR returned +91. 0% versus ADTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protara Therapeutics, Inc.

(TARA) is the lower-risk stock at 1. 16β versus Telomir Pharmaceuticals, Inc. Common Stock's 1. 91β — meaning TELO is approximately 64% more volatile than TARA relative to the S&P 500. On balance sheet safety, Protara Therapeutics, Inc. (TARA) carries a lower debt/equity ratio of 2% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ICON Public Limited Company (ICLR) is pulling ahead at 2.

0% versus -79. 2% for Aditxt, Inc. (ADTX). On earnings-per-share growth, the picture is similar: Telomir Pharmaceuticals, Inc. Common Stock grew EPS 41. 1% year-over-year, compared to -38. 6% for Aditxt, Inc.. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -257. 1% for Aditxt, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICLR leads at 13. 3% versus -208. 0% for ADTX. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TARA: 123.

5% to $12. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protara Therapeutics, Inc.

(TARA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16)). Telomir Pharmaceuticals, Inc. Common Stock (TELO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TARA: -98. 3%, TELO: -81. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TELO is a small-cap quality compounder stock; TARA is a small-cap quality compounder stock; ADTX is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.